Continuous Glucose Monitoring: The Complete 2026 Guide

The core of every CGM is an electrochemical biosensor — a fine, flexible filament roughly 500–700 micrometres in diameter that sits just beneath the skin in the interstitial fluid compartment. The sensor tip is coated with the enzyme glucose oxidase (GOx), which catalyses the oxidation of glucose to gluconic acid. This reaction releases electrons that are captured at a working electrode, generating a small amperometric current directly proportional to local glucose concentration. The signal is transmitted via a micro-processor in the transmitter cap, which applies calibration algorithms and temperature correction before sending the reading via Bluetooth Low Energy to the paired device.

The critical nuance is that CGM does not measure blood glucose directly — it measures glucose in the interstitial fluid, which lags capillary blood glucose by approximately 5–15 minutes under stable conditions and by up to 20–25 minutes during rapid glucose changes such as those occurring during a meal. This physiological lag is well-characterised: a 2020 study in Diabetes Technology and Therapeutics by Siegmund and colleagues measured a mean lag of 9.6 minutes across 40 subjects using the Libre 2 system. Manufacturers partially compensate for this with predictive algorithms that estimate the blood glucose trend, but the lag remains a source of error during the steepest parts of the post-meal glucose curve.

Accuracy is conventionally reported as Mean Absolute Relative Difference (MARD) against a reference method — usually a Yellow Springs Instruments (YSI) analyser, considered the gold standard. MARD represents the average percentage error across all paired readings. A MARD of 9% means that at any given moment, the CGM reading is on average 9% away from the true blood glucose value. Accuracy is systematically lower below 70 mg/dL (3.9 mmol/L), where the glycaemic gradient in interstitial fluid is smallest and the signal-to-noise ratio in the electrochemical reaction is reduced. The FDA requires sensors to meet a MARD of ≤10% in the 70–400 mg/dL range for approval; the clinically meaningful threshold for decision-support is generally accepted as ≤10% in expert consensus.

The Dexcom G7, cleared by the FDA in December 2022 and widely adopted through 2024–2026, represents the current clinical standard for type 1 diabetes management. Its pivotal trial reported an overall MARD of 8.2% across 115 adults and 36 paediatric subjects, with a sensor wear period of 10 days and a one-hour warmup time following insertion. The G7 integrates natively with automated insulin delivery (AID) systems including Tandem Control-IQ and Omnipod 5, and its share time feature allows up to ten followers to monitor a user's glucose remotely. Dexcom's Stelo — launched in 2024 as an OTC device for non-diabetic users — uses a modified G7 sensor with alarms disabled by default and a 15-day wear period, reporting 9.1% MARD in its consumer population study.

Abbott's Libre 3, the successor to the original FreeStyle Libre and Libre 2, achieved CE marking in Europe in 2022 and FDA clearance in 2023 for ages two and above. It reported 7.8% MARD in a 2022 pivotal study published in Diabetes Care (Haak et al.) across 98 adult subjects, with a 14-day sensor life and real-time streaming to both iOS and Android. Abbott also markets the Lingo — its consumer CGM targeted at healthy users and athletes — which uses a 14-day Libre 3 sensor but pairs with a distinct coaching app focused on glucose zones and meal scoring rather than clinical alerts. Lingo's published accuracy data in the non-diabetic user population suggests approximately 9.5% MARD, partly attributable to the narrower glucose range over which non-diabetics fluctuate, which compresses statistical variance. Medtronic's Guardian 4, Dexcom's G6 Pro (clinic-facing), and several Chinese-market sensors (including the Sibionics and the Sinocare Safe-Accu) round out the 2026 landscape, though the latter two lack FDA clearance.

A head-to-head accuracy comparison published in the Journal of Diabetes Science and Technology in 2025 (Tauschmann et al.) evaluated G7, Libre 3, and the now-discontinued Medtronic Guardian Sensor 3 under controlled inpatient conditions in 30 adults with type 1 diabetes, with a YSI reference every 15 minutes over 48 hours. Overall MARD was 8.1% (G7), 7.9% (Libre 3), and 11.3% (Guardian 3). Crucially, in the hypoglycaemic range (<70 mg/dL), all three sensors showed MARD increases of 2–4 percentage points above their overall figures, and in the overnight fasting period — when glucose is most stable — all three performed better than average, with G7 achieving 6.3% MARD and Libre 3 achieving 6.1% during the 00:00–06:00 window.

HbA1c — glycated haemoglobin — reflects the proportion of haemoglobin molecules that have been non-enzymatically glycated over the preceding 90 days, providing an integrated average of glucose exposure. For decades it was the primary outcome measure in diabetes trials, and it remains essential for diagnosis and population-level risk stratification. Its limitation is mathematical: an HbA1c of 7.0% (53 mmol/mol) can arise from a person spending most of the day at 100 mg/dL with occasional spikes to 250 mg/dL, or from a person oscillating between 55 mg/dL and 190 mg/dL throughout the day. These profiles carry different risk implications — the latter involves both significant hyperglycaemic excursions and recurrent hypoglycaemia — yet they are invisible to a single three-month average.

Time in Range (TIR) emerged as the primary CGM-derived metric in the 2019 Ambulatory Glucose Profile consensus (Battelino et al., Diabetes Care). The standard TIR target for people with type 1 or type 2 diabetes is 70–180 mg/dL for more than 70% of the day, with time below range (TBR, <70 mg/dL) held below 4% and time very low (<54 mg/dL) below 1%. These targets were validated against retinopathy, nephropathy, and neuropathy outcomes in longitudinal cohort data. A landmark analysis by Beck et al. in Diabetes Care 2019 demonstrated that each 10 percentage-point improvement in TIR was associated with a 64% reduction in the risk of retinopathy progression — a more powerful signal than the same-sized improvement in HbA1c. For non-diabetics, loose consensus targets suggest TIR >90% for the 70–140 mg/dL range, though this narrower band lacks the outcome-validated evidence base of the diabetic TIR literature.

Beyond TIR, coefficient of variation (CV) — the standard deviation of glucose divided by the mean, expressed as a percentage — captures glucose variability independent of the average. A CV of ≤36% is considered low variability in diabetes management guidelines; CVs above 36% are associated with higher hypoglycaemia risk and worse quality-of-life scores independent of HbA1c. Mean Amplitude of Glycaemic Excursions (MAGE) and J-index are older metrics now largely superseded by TIR and CV in clinical practice, but remain used in research settings. For precision medicine applications, combining TIR, CV, and the time profile of CGM data — particularly the postprandial area under the curve (AUC) in the first two hours after a meal — provides a multidimensional metabolic fingerprint that no single blood test can replicate.

The interest in CGM among metabolically healthy individuals accelerated dramatically after two high-profile studies demonstrated that even people without diabetes spend substantial time above 140 mg/dL. A 2018 study by Bent and colleagues at Stanford (PLOS Biology) in 57 non-diabetic volunteers found that participants spent a median of 26% of their time above 140 mg/dL on a standard diet, and that individual glucose responses to identical foods varied by up to 40%. A follow-up study by the Sonnenburg and Gardner laboratories (Cell Metabolism, 2022) in 36 healthy adults showed that individuals classified as insulin-sensitive still exhibited postprandial glucose excursions that predicted inflammatory cytokine levels measured via proteomics — suggesting that even transient mild hyperglycaemia below the diagnostic threshold carries mechanistic relevance.

The more rigorous NutriCode trial (Mendes-Soares et al., Cell Host Microbe, 2021) enrolled 327 non-diabetic adults in a two-week CGM-plus-microbiome study and demonstrated that a personalised dietary recommendation algorithm trained on CGM response, gut microbiome composition, and anthropometrics outperformed a standard low-glycaemic diet in reducing postprandial glucose AUC by 16% over four weeks. This provided the first controlled evidence that CGM-guided dietary adjustment in healthy people can measurably alter a metabolic proxy endpoint. However, the trial did not follow participants to hard clinical outcomes — cardiovascular events, metabolic disease incidence — and its four-week duration leaves open the question of whether glucose improvements persist or are metabolically compensated.

Critically, a 2024 systematic review in Annals of Internal Medicine (Olson et al.) evaluated 11 randomised trials of CGM in people without diabetes and concluded that there was no evidence of benefit on HbA1c, fasting glucose, BMI, or blood pressure compared to standard dietary counselling alone — though all trials were 12 weeks or shorter. The authors noted that selection bias, lack of blinding, and small sample sizes limited the conclusions. The honest summary for 2026: CGM in healthy people is an excellent tool for pattern recognition and personalisation, but it has not yet been shown in a powered RCT to prevent disease. The device is a learning instrument, not a therapeutic intervention — the value depends entirely on whether the user translates observations into durable behaviour change.

In endurance sports, carbohydrate availability is the primary determinant of high-intensity performance, and CGM provides a direct window into fuel status that perceived exertion alone cannot replicate. During sustained aerobic exercise at 65–75% VO₂max, skeletal muscle glucose uptake increases 7–20-fold via GLUT4 translocation, typically producing a progressive fall in CGM readings over 60–90 minutes that mirrors muscle glycogen depletion. A 2023 study from the research group at Loughborough University's National Centre for Sport and Exercise Medicine (Moulton et al., International Journal of Sport Nutrition and Exercise Metabolism) followed 28 trained cyclists over four weeks, finding that CGM-guided pre-workout carbohydrate intake — targeting a CGM reading above 90 mg/dL at workout initiation — improved sustained power output at 90% FTP by 4.7% compared to the control group using perceived hunger as their pre-workout fuelling cue.

One counterintuitive CGM finding for athletes is the paradoxical glucose rise seen during high-intensity efforts above approximately 80% VO₂max and during resistance training. This occurs because sympathetic nervous system activation releases catecholamines that stimulate hepatic glycogenolysis and gluconeogenesis faster than the exercising muscle can uptake glucose, transiently pushing CGM readings to 160–200 mg/dL despite high energy expenditure. This is a normal physiological stress response and should not be interpreted as pathological hyperglycaemia. Researchers at the University of Colorado Anschutz Medical Campus documented a mean CGM rise of 47 mg/dL during 30-second Wingate sprint tests in 22 trained male cyclists, returning to baseline within 30 minutes post-effort (Scott et al., Applied Physiology, Nutrition, and Metabolism, 2022).

Post-exercise hypoglycaemia is the other key application area. Prolonged exercise depletes muscle and hepatic glycogen, and the enhanced insulin sensitivity following a session can produce CGM dips below 70 mg/dL for up to four hours post-workout — a window that coincides with protein synthesis maxima and is often not consciously perceived as hypoglycaemia. CGM data from the Loughborough group showed that 34% of post-exercise readings in their cyclist cohort fell below 70 mg/dL within 90 minutes of session completion, with the highest risk in athletes who completed sessions in a fasted state. For athletes trying to time carbohydrate intake relative to lactate threshold, CGM does not directly measure blood lactate — but the inflection point in the CGM glucose curve (where the progressive fall during sub-threshold work transitions to a plateau or slight rise, driven by increasing gluconeogenic drive) has been proposed as a metabolic threshold proxy, though this relationship requires further validation before it can substitute for lactate testing.

The most consistent surprise for first-time CGM users is the magnitude and duration of glucose spikes from foods they consider healthy. White rice — particularly sushi-style sticky rice — is a consistent high-spike food even in lean, insulin-sensitive individuals: the Weizmann Institute's landmark personalised nutrition study (Zeevi et al., Cell, 2015) in 800 non-diabetic Israelis found that sushi was among the highest-spiking foods despite its moderate glycaemic index, largely because portion sizes are large and the rice is cooked to a high starch gelatinisation that accelerates digestion. Ripe bananas, sports drinks, and oat-based breakfast cereals also produce spikes that surprise users who associate "natural" or "whole" foods with metabolic safety. Conversely, pasta — particularly al dente, lower-GI pasta — frequently produces lower spikes than expected because the dense protein-starch matrix slows amylase access to starch granules.

Meal context dramatically modifies the glucose response curve. The sequence in which macronutrients are consumed matters: a 2015 study by Shukla and colleagues in Diabetes Care found that eating protein and vegetables before carbohydrates reduced the 30-minute postprandial glucose peak by 29% and the 60-minute AUC by 37% compared to eating carbohydrates first — a finding that has been replicated in multiple subsequent studies. Vinegar ingestion (15–30 mL of apple cider vinegar) reduces postprandial glucose by 20–34% across several trials, attributed to acetic acid inhibiting α-amylase activity and enhancing muscular glucose uptake via AMPK activation. The addition of fat to a carbohydrate load — butter on bread, olive oil in pasta — blunts the immediate spike but extends the duration of elevated glucose and shifts the peak rightward, sometimes resulting in a higher late-phase AUC despite a lower early peak, which CGM visualises clearly but standard finger-stick testing at a single time point misses entirely.

Sleep deprivation is among the most dramatic non-food spike triggers visible on CGM. A 2010 study by Donga and colleagues (Journal of Clinical Endocrinology and Metabolism) showed that a single night of sleep restriction to four hours in healthy subjects increased postprandial glucose AUC the following morning by 23% compared to a full-night condition, with a corresponding 20% reduction in insulin secretion. CGM users frequently observe this themselves — a breakfast eaten after a five-hour sleep night produces a noticeably higher and more prolonged spike than the same breakfast eaten after eight hours, providing immediate personalised feedback that sleep has metabolic consequences. Stress and cortisol elevation produce similar CGM-visible effects, as cortisol stimulates hepatic glucose output directly via glucocorticoid receptor activation of G6Pase and PEPCK, the rate-limiting enzymes of gluconeogenesis.

The most informative metabolic picture emerges when CGM data is interpreted alongside autonomic and hormonal signals. Heart rate variability (HRV) — a measure of beat-to-beat variation in the RR interval of the ECG, reflecting parasympathetic tone and autonomic flexibility — shows a robust inverse relationship with mean glucose and glucose variability in multiple studies. Research from the University of Auckland (Moltchanova et al., Diabetes Research and Clinical Practice, 2019) in 112 adults with type 2 diabetes found that HRV (measured as RMSSD) was significantly lower in the tertile with highest glucose variability (CV >36%) compared to the most stable tertile, independent of HbA1c. The mechanism involves glycation of autonomic nerve fibre proteins and direct mitochondrial impairment in sinoatrial node cells under hyperglycaemic conditions, reducing the metabolic flexibility of the autonomic nervous system.

Sleep quality and glucose metabolism are bidirectionally linked, and CGM-plus-sleep tracking can reveal this loop in real time. Poor sleep architecture — specifically reduced slow-wave (N3) sleep — is associated with 20–25% reductions in insulin sensitivity the following day, a relationship documented in clinical sleep laboratory studies using hyperinsulinaemic-euglycaemic clamp methodology. Wearable sleep trackers (Oura Ring, Garmin) can broadly differentiate disrupted versus undisrupted nights, and pairing these with CGM allows users to observe how their glucose trajectory on a given day is shaped by what happened the night before. A notable finding from the Level Health (now acquired by Abbott) user dataset — published as a preprint in 2023 and covering 4,700 CGM users — was that nights scored by Oura as below 70% sleep quality predicted a 12% higher mean glucose and 31% greater peak postprandial AUC the following day, even after controlling for diet and activity.

Cortisol integration adds the third dimension. Morning cortisol — measured via salivary cortisol kits, the Cortisol Wrist (Epicore Biosystems), or dried blood spot at-home testing — peaks at approximately 20–30 minutes after waking (the cortisol awakening response, CAR) and is a direct driver of the Dawn Phenomenon: the early-morning CGM rise seen in people with insulin resistance as hepatic glucose output exceeds peripheral uptake. A high CAR (>18 nmol/L increase from baseline) predicts a higher fasting CGM reading and a steeper breakfast spike. Multi-biomarker platforms including the Levels Health SDK, Ultrahuman's metabolic dashboard, and QuanMed AI's own biomarker stack are building integrations that overlay CGM, HRV, sleep staging, and cortisol into composite readiness scores — though the clinical validation for these combined scores remains early-stage compared to the individual biomarker literatures.

Alert fatigue is the most clinically significant behavioural limitation of CGM in diabetes management. Modern CGMs offer customisable alarms for high glucose, low glucose, and rapid rate-of-change events, with the intent of preventing dangerous hypoglycaemia and enabling timely intervention. In practice, alert density becomes a major burden: a 2021 study in Diabetes Technology and Therapeutics (Tauschmann et al.) found that children with type 1 diabetes on CGM received a median of 14 alarms per day, and parents reported silencing 65% of alerts within 90 days. Alarm fatigue was associated with lower parental sleep quality (measured by Actiwatch) and, counterintuitively, with reduced CGM benefit — users who silenced alarms frequently had worse TIR outcomes than light alarm users, suggesting that the alert system was consuming attentional bandwidth without delivering proportionate protection. The solution being explored in 2026 devices is adaptive alarm thresholds that learn from user patterns and escalate through a hierarchy of less-to-more obtrusive notifications before triggering an audible alert.

For non-diabetic CGM users, the emerging controversy is the risk of glucose-monitoring-induced orthorexia nervosa — a pattern of increasingly rigid and restrictive food choices driven by anxiety about CGM readings rather than clinical necessity. A 2024 systematic review in the Journal of Eating Disorders (Hendricks et al.) synthesised 14 studies involving 1,847 non-diabetic CGM users and identified a significant association between CGM use and elevated Eating Attitudes Test (EAT-26) scores, particularly in individuals with pre-existing anxiety, perfectionist traits, or prior disordered eating history. The phenomenon is mechanistically plausible: CGM provides immediate, highly salient feedback on every food choice, creating the operant conditioning conditions for avoidance behaviour. The authors did not recommend against CGM use but called for screening questionnaires before prescribing CGM for wellness purposes and for app design that contextualises spikes rather than presenting them as simple danger signals.

Accuracy in the hypoglycaemic range (<70 mg/dL) remains an unresolved technical limitation with direct patient-safety implications. The FDA's MARD requirement does not include a specific sub-70 mg/dL standard, and manufacturers typically present MARD data in the 70–400 mg/dL range, obscuring performance at the clinically most dangerous glucose levels. A 2023 analysis by Heinemann and colleagues in Diabetologia pooled accuracy data from 38 CGM studies across the G7, Libre 3, Libre 2, G6, and Guardian Sensor 3, finding that below 70 mg/dL, aggregate MARD rose from ~8% to ~15.7%, and that 11.4% of readings below 60 mg/dL were falsely classified as within the 70–180 mg/dL target range. This means that CGM cannot be used as the sole trigger for hypoglycaemia treatment decisions — confirmatory finger-stick testing before treating a low CGM reading remains standard of care. For non-diabetic users, this limitation is less clinically critical but should inform realistic expectations about what the technology can and cannot reveal in the fasting or post-exercise low-glucose range.